Abridge Secures Strategic Investment From Eli Lilly, Expands AI Platform Into Payer and Research Workflows
Advertisement
The move extends Abridge’s capabilities beyond ambient clinical documentation into claims management, coding, prior authorization, and research support.
Healthcare AI company Abridge has secured a strategic investment from pharmaceutical major Eli Lilly and Company while unveiling a significant expansion of its platform to support payer, reimbursement, clinical decision support, and research workflows.
The announcement was made by Abridge CEO and co-founder Dr. Shiv Rao during an event in New York City. Financial details of the investment were not disclosed.
The company said its expanded platform is designed to connect clinical care, payment processes, and evidence-based treatment through what it describes as an AI-native clinician intelligence platform. The move extends Abridge’s capabilities beyond ambient clinical documentation into claims management, coding, prior authorization, and research support.
According to the company, the platform now aligns real-time clinical documentation with claims workflows, enabling healthcare providers and payers to reduce administrative rework, accelerate patient services, and support faster reimbursement processes. The company is also targeting greater automation in insurance approvals and claims adjudication.
Abridge has steadily expanded its product portfolio over the past two years. In 2025, it introduced a contextual reasoning engine that generates billable clinical notes at the point of care. It is also collaborating with Highmark Health on AI-powered prior authorization solutions and announced a partnership with Availity earlier this year to accelerate real-time prior authorization processes.
To strengthen coding accuracy and documentation quality, Abridge has entered into a partnership with the American Health Information Management Association (AHIMA). The collaboration will support coding and clinical documentation improvement capabilities across fee-for-service and value-based care models.
The company is also extending its reach into life sciences and clinical research. Abridge said its platform could help health systems identify potential clinical trial candidates and initiate screening pathways during patient encounters.
Abridge currently works with more than 300 health systems, including community health centers, specialty hospitals, and large provider organizations. Its technology supports over 100 million clinical conversations annually and serves healthcare organizations collectively caring for more than 250 million patients. Northwestern Medicine recently announced an enterprise-wide deployment of the platform.
The company also launched new content collaborations with the American Diabetes Association and the American Academy of Family Physicians to expand its clinical decision support capabilities. Additionally, Abridge announced a partnership with the American Heart Association to explore the use of ambient clinical intelligence in cardiovascular research and evidence generation.
Separately, Abridge introduced smart room integrations with Artisight and hellocare.ai, combining AI-powered documentation with virtual care and intelligent inpatient room technologies.
Stay tuned for more such updates on Digital Health News
